Nilotinib Teva Uk (Nilotinib Hydrochloride Dihydrate)

Nilotinib, the active ingredient in Nilotinib Teva Uk, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively targets BCR‑ABL kinase and is indicated for the treatment of chronic myeloid leukemia in adult patients with proven efficacy in clinical trials.

GNH USA supplies Nilotinib Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with reliable logistics and regulatory support.

Nilotinib is used in the treatment of chronic myeloid leukemia, a myeloproliferative disorder driven by BCR‑ABL kinase activity.

- Chronic Myeloid Leukemia (chronic phase): reduces leukemic cell proliferation and helps achieve hematologic and cytogenetic response. - Chronic Myeloid Leukemia (accelerated phase): provides disease control and can delay progression to blast crisis. - Chronic Myeloid Leukemia (blast crisis): contributes to remission induction when combined with other therapies.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Fatigue - Headache - Myalgia

Serious or Rare Side Effects: - Cardiovascular events (e.g., arterial occlusion) - Pancreatitis - Hepatic toxicity (elevated transaminases) - QT interval prolongation - Tumor lysis syndrome - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Nilotinib, clinicians should consider several safety precautions to minimize risk.

- Cardiac monitoring: assess baseline ECG and monitor for ischemic events during therapy. - Liver function: evaluate hepatic enzymes before initiation and periodically thereafter. - Blood glucose: monitor for hyperglycemia, especially in diabetic patients. - Concomitant QT‑prolonging drugs: avoid or use with caution due to risk of arrhythmia. - Severe hepatic impairment: contraindicated or requires dose adjustment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase Nilotinib levels